Patent application number | Description | Published |
20100062156 | Reverse Osmosis Membranes - Reverse osmosis membranes made by interfacial polymerization of a monomer in a nonpolar (e.g. organic) phase together with a monomer in a polar (e.g. aqueous) phase on a porous support membrane. Interfacial polymerization process is disclosed for preparing a highly permeable RO membrane, comprising: contacting on a porous support membrane, a) a first solution containing 1,3-diaminobenzene, and b) a second solution containing trimesoyl chloride, wherein at least one of solutions a) and b) contains nanoparticles when said solutions are first contacted, and recovering a highly permeable RO membrane. | 03-11-2010 |
20120261344 | HYBRID NANOPARTICLE TFC MEMBRANES - Reverse osmosis membranes made by interfacial polymerization of a monomer in a nonpolar (e.g. organic) phase together with a monomer in a polar (e.g. aqueous) phase on a porous support membrane. Interfacial polymerization process is disclosed for preparing a highly permeable RO membrane, comprising: contacting on a porous support membrane, a) a first solution containing 1,3-diaminobenzene, and b) a second solution containing trimesoyl chloride, wherein at least one of solutions a) and b) contains nanoparticles when said solutions are first contacted, and recovering a highly permeable RO membrane. | 10-18-2012 |
20120285890 | HYBRID TFC RO MEMBRANES WITH NON-METALLIC ADDITIVES - A process for preparing a reverse osmosis membrane that includes: (A) providing a polyamine, a polyfunctional acid halide, and a flux increasing additive having the formula Z | 11-15-2012 |
20140050846 | HYBRID NANOPARTICLE TFC MEMBRANES - Reverse osmosis membranes made by interfacial polymerization of a monomer in a nonpolar (e.g. organic) phase together with a monomer in a polar (e.g. aqueous) phase on a porous support membrane. Interfacial polymerization process is disclosed for preparing a highly permeable RO membrane, comprising: contacting on a porous support membrane, a) a first solution containing 1,3-diaminobenzene, and b) a second solution containing trimesoyl chloride, wherein at least one of solutions a) and b) contains nanoparticles when said solutions are first contacted, and recovering a highly permeable RO membrane. | 02-20-2014 |
20140295079 | HYBRID NANOPARTICLE TFC MEMBRANES - Reverse osmosis membranes made by interfacial polymerization of a monomer in a nonpolar (e.g. organic) phase together with a monomer in a polar (e.g. aqueous) phase on a porous support membrane. Interfacial polymerization process is disclosed for preparing a highly permeable RO membrane, comprising: contacting on a porous support membrane, a) a first solution containing 1,3-diaminobenzene, and b) a second solution containing trimesoyl chloride, wherein at least one of solutions a) and b) contains nanoparticles when said solutions are first contacted, and recovering a highly permeable RO membrane. | 10-02-2014 |
20140329010 | HYBRID TFC RO MEMBRANES WITH NON-METALLIC ADDITIVES - A process for preparing a reverse osmosis membrane that includes: (A) providing a polyamine, a polyfunctional acid halide, and a flux increasing additive having the formula Z | 11-06-2014 |
20160030897 | HYBRID NANOPARTICLE TFC MEMBRANES - Reverse osmosis membranes made by interfacial polymerization of a monomer in a nonpolar (e.g. organic) phase together with a monomer in a polar (e.g. aqueous) phase on a porous support membrane. Interfacial polymerization process is disclosed for preparing a highly permeable RO membrane, comprising: contacting on a porous support membrane, a) a first solution containing 1,3-diaminobenzene, and b) a second solution containing trimesoyl chloride, wherein at least one of solutions a) and b) contains nanoparticles when said solutions are first contacted, and recovering a highly permeable RO membrane. | 02-04-2016 |
Patent application number | Description | Published |
20130178709 | METHODS FOR THE PREVENTION OF SURGICAL SITE INFECTIONS - Several methods to reduce surgical site infections include inserting a surgical access device into an incision, retracting tissue, and introducing fluid into the surgical access device such that the fluid exits the surgical access device and irrigates a surgical site. Other methods do not include introducing fluid into a surgical access device but include suctioning a fluid into the surgical access device and removing the fluid from the body. | 07-11-2013 |
20130178710 | SYSTEMS FOR THE PREVENTION OF SURGICAL SITE INFECTIONS - A surgical access system facilitates access to a surgical site within a patient's body through an incision in the body. Surgical access systems can have at least one retention member and a fluid transportation member configured to deliver fluid to a surgical site or to remove fluid from a surgical site. In some embodiments, a surgical access device irrigates a surgical site to reduce surgical site infections and removes fluid from the surgical site to increase a physician's visibility into the surgical site. | 07-11-2013 |
20130184535 | EXPANDABLE TISSUE RETRACTION DEVICES - A surgical access device facilitates access to a surgical site within a patient's body through an incision in the body. Surgical access devices can have a first retention member and a second retention member with a pliable membrane that extends between the first retention member and the second retention member. A retention member can include at least three linkages pivotably coupled to one another such that expanding the retention member causes at least some of the linkages to pivot relative to one another. The pliable membrane can be configured to expand the incision to facilitate access to the surgical site. | 07-18-2013 |
20150272565 | METHODS FOR THE PREVENTION OF SURGICAL SITE INFECTIONS - Several methods to reduce surgical site infections include inserting a surgical access device into an incision, retracting tissue, and introducing fluid into the surgical access device such that the fluid exits the surgical access device and irrigates a surgical site. Other methods do not include introducing fluid into a surgical access device but include suctioning a fluid into the surgical access device and removing the fluid from the body. | 10-01-2015 |
Patent application number | Description | Published |
20130204068 | Apparatus and Methods For Treating Pulmonary Hypertension - A method is described for decreasing activity of at least one sympathetic nerve, nerve fiber or neuron innervating at least one blood vessel in the pulmonary vasculature of a patient to ameliorate pulmonary hypertension. In one embodiment, the method may involve advancing an intravascular treatment device to a target location in a target blood vessel within the pulmonary vasculature of the patient and using the treatment device to decrease activity of at least one sympathetic nerve, nerve fiber or neuron innervating the target blood vessel at or near the target location to ameliorate pulmonary hypertension. | 08-08-2013 |
20140221975 | APPARATUS AND METHODS FOR TREATING PULMONARY HYPERTENSION - A method is described for decreasing activity of at least one sympathetic nerve, nerve fiber or neuron innervating at least one blood vessel in the pulmonary vasculature of a patient to ameliorate pulmonary hypertension. In one embodiment, the method may involve advancing an intravascular treatment device to a target location in a target blood vessel within the pulmonary vasculature of the patient and using the treatment device to decrease activity of at least one sympathetic nerve, nerve fiber or neuron innervating the target blood vessel at or near the target location to ameliorate pulmonary hypertension. | 08-07-2014 |
20150216592 | APPARATUS AND METHODS FOR TREATING PULMONARY HYPERTENSION - A method is described for decreasing activity of at least one sympathetic nerve, nerve fiber or neuron innervating at least one blood vessel in the pulmonary vasculature of a patient to ameliorate pulmonary hypertension. In one embodiment, the method may involve advancing an intravascular treatment device to a target location in a target blood vessel within the pulmonary vasculature of the patient and using the treatment device to decrease activity of at least one sympathetic nerve, nerve fiber or neuron innervating the target blood vessel at or near the target location to ameliorate pulmonary hypertension. | 08-06-2015 |
Patent application number | Description | Published |
20160081597 | SYSTEM AND METHOD FOR MODE SWITCHING - Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user's interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like. | 03-24-2016 |
20160100445 | SYSTEMS AND METHODS FOR PROCESSING AND TRANSMITTING SENSOR DATA - Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are provided. The data can be displayed on a hand-held display device having a display such as a key fob device including a user interface, such as an LCD and one or more buttons allows a user to view data, and a physical connector, such as USB port. | 04-07-2016 |
20160106350 | SYSTEM AND METHOD FOR MODE SWITCHING - Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user's interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like. | 04-21-2016 |
Patent application number | Description | Published |
20110093572 | LOW LEVEL INITIALIZER - Various embodiments of a method of configuring a predefined set of electrically isolated blades to function as a single blade are described. In one embodiment, a configuration rule is accessed, wherein a portion of the configuration rule assigns roles to management processors coupled with the predefined set of conjoined blades of a blade partition. Assistant management processors are directed to configure blade manageability modules to support the assigned roles. The blade manageability modules are coupled with the management processors. In one embodiment, the assistant management processors are directed to configure resources to be shared across the blade partition according to the configuration rule. After determining that the conjoined blades are configured according to the configuration rule, the conjoined blades are initialized. Thus, the conjoined blades are coordinated to function as a single blade. | 04-21-2011 |
20110093574 | MULTI-BLADE INTERCONNECTOR - Various embodiments of the present technology, a method [ | 04-21-2011 |
20110113160 | DOMAIN MANAGEMENT PROCESSOR - Various embodiments of a method [ | 05-12-2011 |
20110145467 | INTERCONNECTING COMPUTING MODULES TO FORM AN INTEGRATED SYSTEM - Systems, methods and portable devices are provided for interconnecting one or more computing modules within an enclosure together to form an integrated system. A portable device may include a communication interface configured to be removably coupled to each computing module for interconnecting them together to form the integrated system. A portable device may also include memory configured to store an integrated system personality that serves as a point of authority for each computing module of the integrated system. The integrated system personality may include an identifier of the integrated system. | 06-16-2011 |
20110145540 | DYNAMICALLY REALLOCATING COMPUTING COMPONENTS BETWEEN PARTITIONS - Systems, methods and computing components are provided for dynamically reallocating a plurality of computing components among one or more logical partitions. A first computing component that is allocated to a first partition may have a management processor. A second computing component may be allocated to a second partition. The management processor of the first computing component may be configured to reallocate the first computing component to a third partition without affecting the second computing component. | 06-16-2011 |
20120014390 | PROCESSOR TOPOLOGY SWITCHES - A first processor has a processor port for peer-to-peer processor communications. A switch provides for switching communications from a path between said first processor and a second processor to a path between said first processor and a third processor (and vice-versa). | 01-19-2012 |
20150326653 | PROCESSOR TOPOLOGY SWITCHES - A first processor has a processor port for peer-to-peer processor communications. A switch provides for switching communications from a path between said first processor and a second processor to a path between said first processor and a third processor (and vice-versa). | 11-12-2015 |
Patent application number | Description | Published |
20090221630 | IAP INHIBITORS - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X | 09-03-2009 |
20100069357 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). | 03-18-2010 |
20100130539 | IMIDAZOPYRIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X | 05-27-2010 |
20100331305 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). | 12-30-2010 |
20110098305 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. | 04-28-2011 |
20110218211 | AZAINDOLE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X | 09-08-2011 |
20120015974 | IMIDAZOPYRIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: | 01-19-2012 |
20120094980 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-19-2012 |
20120165313 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). | 06-28-2012 |
20150105550 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-16-2015 |
20150111879 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-23-2015 |
Patent application number | Description | Published |
20110077265 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3′, R4, R4′ and R5, are as described herein. | 03-31-2011 |
20120270886 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X | 10-25-2012 |